Global expansion Grünenthal operates in 28 countries with products available in about 100 markets, signaling a broad international footprint and potential for regional partnerships, technology transfers, or co-development opportunities across diverse regulatory environments.

M&A and licensing Recent acquisitions and asset investments, including Movantik and global rights deals, indicate openness to strategic acquisitions and licenses that expand the portfolio; sales teams can explore new co-promotion, distribution, or cross-licensing opportunities in adjacent pain and inflammation therapies.

Pain management focus As a leading science-based pain management company, Grünenthal prioritizes innovative therapies and state-of-the-art technologies, presenting a strong case for solution selling around high-value pain and related disease treatments, patient support programs, and digital health integrations.

Sustainability leadership Recognition with EcoVadis Gold Medal reflects strong ESG credentials, which can be leveraged to align with payer and hospital procurement priorities that favor sustainable suppliers, potentially opening initiatives around supply chain transparency and responsible sourcing.

Strategic partnerships Longstanding global collaboration with partners like Apotex to expand patient access abroad suggests receptiveness to channel partnerships, co-market agreements, and regional manufacturing or distribution alliances to accelerate market reach.